FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to oncology, and aims at diagnosing pancreatic adenocarcinoma with a neuroendocrine component. Content of protein TGF-β and its receptor TGFR1 are determined in patient's blood with volumetric formation in pancreas at the stage of examination by immunophenotyping. A ratio of TGF-β to TGFR1 is calculated. If level is 1.32±0.2, adenocarcinoma with a neuroendocrine component is predicted.
EFFECT: invention provides detecting pancreatic neuroendocrine adenocarcinoma at the examination stage.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIFFERENTIAL DIAGNOSING OF PANCREATIC DISEASES | 2019 |
|
RU2732974C1 |
| METHOD FOR CALCULATING LIFE EXPECTANCY OF PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA | 2020 |
|
RU2745793C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF PANCREATIC CANCER | 2019 |
|
RU2742744C1 |
| METHOD FOR PREDICTING CLINICAL COURSE OF HIGHLY DIFFERENTIATED NEUROENDOCRINE PANCREATIC TUMORS | 2020 |
|
RU2747679C1 |
| METHOD OF DIAGNOSING PANCREATIC ADENOCARCINOMA AND METASTASES IN ITS PARENCHYMA | 2018 |
|
RU2699277C1 |
| METHOD OF COMBINED TREATMENT OF UNRESECTABLE CANCER OF EXTRAHEPINOUS BILE DUCTS | 2018 |
|
RU2703330C2 |
| METHOD FOR TREATMENT OF REGIONAL UNRESECTABLE PANCREATIC CANCER | 2017 |
|
RU2663468C1 |
| METHOD FOR PREDICTING THREE-MONTH SURVIVAL IN PATIENTS WITH STAGE IV PANCREATIC CANCER USING PHOTODYNAMIC THERAPY | 2021 |
|
RU2779088C1 |
| METHOD FOR PREDICTION OF DISEASE OUTCOME IN PATIENTS WITH GASTRIC CANCER AFTER SURGICAL MANAGEMENT | 2018 |
|
RU2696054C1 |
| METHOD FOR EARLY DETECTION OF MALIGNANT NEOPLASMS OF PANCREAS IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS | 2023 |
|
RU2822658C1 |
